Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNC | P24863 | 2/20 | 0.41 |
| ▸ | CDK8 | P49336 | 2/20 | 0.41 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.40 |
| ▸ | PARP1 | P09874 | 1/20 | 0.40 |
| ▸ | IRAK4 | Q9NWZ3 | 9/20 | 0.38 |
| ▸ | KCNT1 | Q5JUK3 | 1/20 | 0.37 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.33 |
| ▸ | PIM1 | P11309 | 1/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.33 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9109267 | 0.87 | PARP1 (0.39) | PARP1PDE10AADORA2A | |
| SCHEMBL9106392 | 0.84 | PARP1 (0.47) | CCNCCDK8PARP1PIM1 | |
| SCHEMBL9104561 | 0.80 | PARP1 (0.61) | PARP1MAPK1ADORA2A | |
| SCHEMBL9108917 | 0.80 | PARP1 (0.46) | PIK3CBPARP1 | |
| SCHEMBL9109419 | 0.79 | PARP1 (0.45) | PIK3CBPARP1KCNT1 | |
| SCHEMBL9106568 | 0.79 | RIPK2 (0.47) | PARP1IRAK4MAPK1 | |
| SCHEMBL9107989 | 0.78 | PARP1 (0.46) | PARP1 | |
| SCHEMBL9107219 | 0.76 | PARP1 (0.41) | PARP1 | |
| SCHEMBL9108527 | 0.75 | PARP1 (0.39) | PARP1PIM1 | |
| SCHEMBL1419832 | 0.74 | DHODH (0.63) | PIK3CBPARP1KCNT1PDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8349824-B2 | Triazolopyridine compounds | HOFFMANN-LA ROCHE INC. (US) | 2013-01-08 | — | — | US | disclosed |
| US-20120142665-A1 | TRIAZOLOPYRIDINE COMPOUNDS | HOFFMANN-LA ROCHE INC. | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142665-A1 | TRIAZOLOPYRIDINE COMPOUNDS | PDE5A, PDE3A, PDE3B | CCNC 3432/4885CDK8 1924/4885PIK3CB 2578/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.